<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00484393</url>
  </required_header>
  <id_info>
    <org_study_id>2007-041</org_study_id>
    <nct_id>NCT00484393</nct_id>
  </id_info>
  <brief_title>Tetracaine Compared to Placebo for Reducing Pain With Palivizumab - A Pilot Study</brief_title>
  <official_title>Tetracaine (Ametop®) Compared to Placebo for Reducing Pain Associated With Intramuscular Injection of Palivizumab (Synagis®) - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fraser Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fraser Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a small study known as a pilot study. This pilot study is being done to see if a
      difference in pain from intramuscular palivizumab injection can be detected if tetracaine a
      topical numbing gel is used compared to no medication (placebo). If a difference is found in
      this pilot study, then a larger study may be done to confirm that there is a difference in
      pain experience.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:

      1) To determine if tetracaine 4% gel (Ametop ®) reduces the pain of intramuscular palivizumab
      compared to placebo for pediatric patients between 1 month and 2 years of age.

      Rationale:

      Premedication with a systemic analgesic has not been shown to be effective in reducing the
      pain from an acute localized insult. EMLA and tetracaine have been shown to decrease pain
      associated with immunizations. EMLA requires a 60 minute application, which decreases the
      usefulness in a busy clinic. Tetracaine has a quicker onset of action and therefore may be
      more suitable for use in a busy clinic. Efficacy of tetracaine prior to palivizumab has not
      been reported and therefore it is not known if it can reduce the pain associated with
      intramuscular palivizumab injection.

      Setting:

      Respiratory synctial virus (RSV) clinic in the pediatric outpatient ward at Surrey Memorial
      Hospital.

      Procedure:

      A notice will be posted in the RSV clinic inviting parents to contact research staff if
      interested in participating in this study. When a parent contacts staff about the study, a
      nurse or pharmacist involved in the study will meet with the parent to review eligibility and
      obtain informed consent.

      Once informed consent obtained subject will be randomized by study pharmacist to receive
      either tetracaine 4% gel (Ametop®) or placebo before administration of the next palivizumab
      injection (study injection 1); a 4 block randomization design will be used. At the next
      injection (study injection 2) the subject will receive either tetracaine or placebo,
      whichever agent they did not receive at study injection 1. The subjects will serve as their
      own control.

      The placebo (Aquatain; Whitehall-Robins, Mississauga, Ontario, Canada) is visually and
      cosmetically similar to tetracaine 4% gel. One gram of drug or placebo will be dispensed in
      unit dose 5mL oral syringes, heat sealed to prevent evaporation and stored in a refrigerator
      for up to one week, after which it will be discarded if unused and redispensed. Tetracaine is
      commercially available in 1.5g tubes that produce approximately 1g tetracaine.

      On the day of immunization and on arrival to the clinic, a clinic nurse who is unaware of the
      treatment assignment will apply 1g of tetracaine or placebo to the subject's thigh and cover
      it with a dressing (opcit; Smith and Nephew). They will record the time of the application of
      the study gel. The clinic nurse will remove the dressing and study gel after 30-45 minutes
      and record the time of removal. The gel will be wiped from the skin with a paper tissue. A
      4-point scale (none, mild, moderate, and severe) will be used to assess local skin reactions
      after removing study gel. Immediately before the injection the site will be cleaned with an
      alcohol swab, then the dose (15mg/kg using current weight) of palivizumab will be
      administered using a ½ - 5/8 inch 23-25 gauge needle. A RSV clinic nurse will inject
      palivizumab within several minutes of gel removal; clinic nurses will not be aware of the
      treatment assignment for the subjects.

      Study injection 1 and 2 will be video recorded. A mirror will be mounted so the video
      recorder can capture the subject's reaction both face on and from the mirror image. The
      videotape will continue until the subject calms down following the injection. The subject can
      be held by a parent during the injection and provide whatever usual comfort measures they
      would provide. Following the injection the parent will be asked questions to determine their
      interpretation of the subject's pain response to the injections and if there any factors that
      may affect the pain response.

      Once both study injections are completed the video will be reviewed and pain assessed for
      both injections by the same scorer using FLACC pain scale. The scorer will be one pediatric
      registered nurse who is competent in completing pain analysis for infants. The scorer will be
      blind as to which dose is tetracaine and which is placebo.

      Data Collection:

      The data collected will include the FLACC pain scale, parent assessment of patient's pain,
      factors affecting pain response, as well as identify adverse effects from tetracaine and
      placebo.

      Sample size and statistical Analysis:

      The number of subjects with informed consent will determine sample size. Statistical analysis
      will involve descriptive statistics only.

      Ethics:

      Confidentiality will always be maintained. No information as to the identify of the child
      will be placed on the data collection forms. Every child will be assigned a number to
      facilitate identification by the researchers. Informed consent will be obtained.

      Personnel:

      A team consisting of nurses, a physician, and a clinical pharmacist from SMH will conduct the
      study. All personnel are currently involved in the day-to-day management of these children
      and have the required expertise in carrying out this project.

      Timeline:

      The study will be submitted for ethical approval by the research ethics board, Fraser Health
      in April 2007. After approval anticipate patient enrolment to start in November 2007 and
      complete enrolment by March 2008. A further 4 months will be needed to analyze the data and
      prepare a manuscript. Expected completion date for the project is July 2008.

      Budget:

      No additional costs are expected for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine if a Difference in Pain Scale Ratings is Detectable Following Intramuscular Palivizumab Injection That Was Pre-treated With Placebo or Tetracaine.</measure>
    <time_frame>2 visits, 1 month apart</time_frame>
    <description>Parent score 1-10 (1 representing no pain and 10 representing extreme pain) FLACC (Face, Legs, Activity, Cry, Consolability) Score 0-10 (at baseline and post injection) (0 representing no pain and 10 representing extreme pain) Change in FLACC score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Tetracaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tetracaine 4% gel 1g applied to injection site</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream (Aquatain) 1g applied to inejction site</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetracaine 4% gel</intervention_name>
    <description>tetracaine applied prior to 1 injection</description>
    <arm_group_label>Tetracaine</arm_group_label>
    <other_name>Ametop</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo applied prior to 1 injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Aquatain used as placebo to look like tetracaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants between 1 month and 2 years of age receiving palivizumab at Surrey Memorial
             Hospital for 2 consecutive intramuscular injections during the 2007/8 season

          -  Parents need to complete informed consent.

        Exclusion Criteria:

          -  Allergy/sensitivity to tetracaine, or ester type anaesthetics.

          -  Infants who present with fever or illness that prevent administration of palivizumab.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandi D Newby, BScPharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Surrey Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surrey Memorial Hospital</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Young KD. Pediatric procedural pain. Ann Emerg Med. 2005 Feb;45(2):160-71. Review.</citation>
    <PMID>15671974</PMID>
  </reference>
  <reference>
    <citation>Anand KJ, Hickey PR. Pain and its effects in the human neonate and fetus. N Engl J Med. 1987 Nov 19;317(21):1321-9. Review.</citation>
    <PMID>3317037</PMID>
  </reference>
  <reference>
    <citation>Weisman SJ, Bernstein B, Schechter NL. Consequences of inadequate analgesia during painful procedures in children. Arch Pediatr Adolesc Med. 1998 Feb;152(2):147-9.</citation>
    <PMID>9491040</PMID>
  </reference>
  <reference>
    <citation>Jacobson RM, Swan A, Adegbenro A, Ludington SL, Wollan PC, Poland GA; Vaccine Research Group. Making vaccines more acceptable--methods to prevent and minimize pain and other common adverse events associated with vaccines. Vaccine. 2001 Mar 21;19(17-19):2418-27. Review.</citation>
    <PMID>11257372</PMID>
  </reference>
  <reference>
    <citation>Meyerhoff AS, Weniger BG, Jacobs RJ. Economic value to parents of reducing the pain and emotional distress of childhood vaccine injections. Pediatr Infect Dis J. 2001 Nov;20(11 Suppl):S57-62.</citation>
    <PMID>11704725</PMID>
  </reference>
  <reference>
    <citation>O'Brien L, Taddio A, Ipp M, Goldbach M, Koren G. Topical 4% amethocaine gel reduces the pain of subcutaneous measles-mumps-rubella vaccination. Pediatrics. 2004 Dec;114(6):e720-4.</citation>
    <PMID>15574604</PMID>
  </reference>
  <reference>
    <citation>Halperin BA, Halperin SA, McGrath P, Smith B, Houston T. Use of lidocaine-prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate and hepatitis B vaccines in infants from birth to six months of age. Pediatr Infect Dis J. 2002 May;21(5):399-405.</citation>
    <PMID>12150176</PMID>
  </reference>
  <reference>
    <citation>Suresh G, Zempsky WT, Schechter NL, Fox JL, Connor EM, Carlin D, Top FH, Weisman LE. IMpact-RSV Study Group Report. Pediatrics 1999;104(4):993-5.</citation>
  </reference>
  <reference>
    <citation>Merkel SI, Voepel-Lewis T, Shayevitz JR, Malviya S. The FLACC: a behavioral scale for scoring postoperative pain in young children. Pediatr Nurs. 1997 May-Jun;23(3):293-7.</citation>
    <PMID>9220806</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2007</study_first_submitted>
  <study_first_submitted_qc>June 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2007</study_first_posted>
  <results_first_submitted>March 5, 2015</results_first_submitted>
  <results_first_submitted_qc>March 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 18, 2015</results_first_posted>
  <last_update_submitted>May 22, 2015</last_update_submitted>
  <last_update_submitted_qc>May 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fraser Health</investigator_affiliation>
    <investigator_full_name>Brandi Newby</investigator_full_name>
    <investigator_title>Clinical Pharmacy Specialist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetracaine</mesh_term>
    <mesh_term>Palivizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tetracaine Then Placebo</title>
          <description>Tetracaine 4% gel 1g applied to injection site prior to next palivizumab injection after enrollment Placebo cream (Aquatain) 1g applied to inejction site prior to subsequent palivizumab injection (1 month after 1st study injection)</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Tetracaine</title>
          <description>Placebo cream (Aquatain) 1g applied to inejction site prior to next palivizumab injection after enrollment Tetracaine 4% gel 1g applied to injection site prior to subsequent palivizumab injection (1 month after 1st study injection)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tetracaine First</title>
          <description>Tetracaine 4% gel 1g applied to injection site first, then placebo with subsequent injection</description>
        </group>
        <group group_id="B2">
          <title>Placebo First</title>
          <description>Placebo cream (Aquatain) 1g applied to inejction site first, then tetracaine with subsequent injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2-6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Determine if a Difference in Pain Scale Ratings is Detectable Following Intramuscular Palivizumab Injection That Was Pre-treated With Placebo or Tetracaine.</title>
        <description>Parent score 1-10 (1 representing no pain and 10 representing extreme pain) FLACC (Face, Legs, Activity, Cry, Consolability) Score 0-10 (at baseline and post injection) (0 representing no pain and 10 representing extreme pain) Change in FLACC score</description>
        <time_frame>2 visits, 1 month apart</time_frame>
        <population>Each participant was evaluated for repsonse following tetracaine and following placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Tetracaine</title>
            <description>Tetracaine 4% gel 1g applied to injection site</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream (Aquatain) 1g applied to inejction site</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine if a Difference in Pain Scale Ratings is Detectable Following Intramuscular Palivizumab Injection That Was Pre-treated With Placebo or Tetracaine.</title>
          <description>Parent score 1-10 (1 representing no pain and 10 representing extreme pain) FLACC (Face, Legs, Activity, Cry, Consolability) Score 0-10 (at baseline and post injection) (0 representing no pain and 10 representing extreme pain) Change in FLACC score</description>
          <population>Each participant was evaluated for repsonse following tetracaine and following placebo</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Parent score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="O2" value="7.3" lower_limit="5" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLACC at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLACC post injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="O2" value="9.3" lower_limit="8" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in FLACC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O2" value="7.7" lower_limit="3" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tetracaine</title>
          <description>Tetracaine 4% gel 1g applied to injection site
tetracaine 4% gel: tetracaine applied prior to 1 injection</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo cream (Aquatain) 1g applied to inejction site
Placebo: placebo applied prior to 1 injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Local skin reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brandi Newby</name_or_title>
      <organization>Fraser Health</organization>
      <phone>604-585-5666 ext 774374</phone>
      <email>brandi.newby@fraserhealth.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

